Humaid Al-Shamsi, Chief Executive Officer at Burjeel Cancer Institute and Regional Director of Burjeel Oncology GCC at Burjeel Holdings, shared a post on LinkedIn:
“Pioneering Cancer Treatment in the UAE & GCC
At Burjeel Cancer Institute | BCI, we are proud to introduce a groundbreaking innovation: the first Hepatic Arterial Infusion Pump (HAIP) in the UAE and GCC.
This advanced therapy delivers high-dose chemotherapy directly into the hepatic artery, targeting liver metastases with precision. HAIP is especially valuable for:
• Adjuvant treatment after colorectal cancer resection to reduce recurrence
• Conversion therapy, turning unresectable liver metastases into resectable ones
• Primary intrahepatic cholangiocarcinoma
Why HAIP matters:
• Targeted therapy – maximizes drug concentration in the liver while minimizing systemic side effects
• Improved outcomes – effectively shrinks tumors, raises resection rates, and enhances quality of life
• Personalized care – delivered by our expert GI oncology and surgical teams
FDA approved and National Comprehensive Cancer Network (NCCN) this world-class technology reflects our commitment to advancing cancer care.
At BCI, we’re not only treating cancer – we’re transforming lives.
Burjeel Cancer Institute: Leading cancer care in the UAE and beyond.”
Proceed to the video attached in the post.
Read more posts featuring Humaid Al-Shamsi on OncoDaily.